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ABSTRACT
Diffuse malignant mesothelioma (DMM) is one of the prognostically most discouraging cancers with
median survivals of only 12–22 months. Due to its insidious onset and delayed detection, DMM is often at
an advanced stage at diagnosis and is considered incurable. Combined chemo- and radiotherapy followed
by surgery only marginally affect outcome at the cost of signiﬁcant morbidity. Because of the long time
period between exposure to asbestos and disease onset, the incidence of DMM is still rising and predicted
to peak around 2020. Novel markers for the reliable diagnosis of DMM in body cavity effusion specimens
as well as more effective, targeted therapies are urgently needed. Here, we show that the “don’t eat me”
signalling molecule CD47, which inhibits phagocytosis by binding to signal regulatory protein a on
macrophages, is overexpressed in DMM cells. A two-marker panel of high CD47 expression and BRCA1-
associated protein 1 (BAP-1) deﬁciency had a sensitivity of 78% and speciﬁcity of 100% in discriminating
DMM tumour cells from reactive mesothelial cells in effusions, which is superior to the currently used four-
marker combination of BAP-1, glucose transporter type 1, epithelial membrane antigen and desmin. In
addition, blocking CD47 inhibited growth and promoted phagocytosis of DMM cell lines by macrophages
in vitro. Furthermore, DMM tumours in surgical specimens from patients as well as in a mouse DMM model
expressed high levels of CD47 and were heavily inﬁltrated by macrophages. Our study demonstrates that
CD47 is an accurate novel diagnostic DMM biomarker and that blocking CD47 may represent a promising
therapeutic strategy for DMM.
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Introduction
Diffuse malignant mesothelioma (DMM), a cancer that originates
from mesothelial cells lining the pleural, pericardial, and abdomi-
nal cavities including the testis, is mainly caused by asbestos
exposure.1 The annual incidence of DMM varies between coun-
tries and is estimated to be 0.8 – 2.9 per 100’000 people. Depend-
ing on the stage and the modality of treatment, median survival
is between 12 and 22 months, making DMM one of the prognos-
tically most discouraging human malignancies.2 This is in part
related to diagnostic delay associated with its typically insidious
onset and the difﬁculties of early diagnosis. DMM commonly
presents with pleural, pericardial or peritoneal effusion, but diag-
nosis of DMM is notoriously difﬁcult by effusion cytology or his-
tology at an early stage given that benign reactive mesothelial
cells may demonstrate degrees of cytological atypia that overlap
with that of DMM.3 Furthermore, DMM shows limited sensitiv-
ity to chemotherapy and irradiation, which makes surgery the
mainstay of therapy for the minority of patients with tumours
amenable to resection – and results in a need of targeted thera-
pies for those with advanced disease.4
A large variety of biomarkers have been studied for their
ability to discriminate between benign and malignant meso-
thelial cells in cytological effusion specimens. Until recently,
the best studied immunophenotypic aberrations in malignant
as opposed to reactive mesothelial cells were overexpression
of epithelial membrane antigen (EMA) or glucose trans-
porter type 1 (GLUT-1) and loss of desmin expression, all of
which suffer, however, from suboptimal sensitivity and speci-
ﬁcity.3,5,6 Loss of CDKN2A, as detected by ﬂuorescence in-
situ hybridisation (FISH), has reasonable sensitivity (around
70%) and is, according to several studies, 100% speciﬁc for
DMM in contradistinction from reactive mesothelial cells,
thereby allowing for a deﬁnite diagnosis of malignancy in
cytological samples.7-9 However, longer turnaround times
and higher costs limit the widespread applicability of FISH,
especially in cases with a lower level of suspicion for DMM.
Recently, loss of expression of BRCA1-associated protein 1
(BAP-1) due to inactivating mutations and/or chromosomal
loss10 has emerged as a marker of malignancy in mesothelial
cells that has a sensitivity similar to that of FISH for
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CDKN2A and an identical 100% speciﬁcity, but can be reli-
ably assessed by immunostaining.8,11
In recent years, cancer immunotherapies that interfere with
immune-inhibitory receptors mainly on T cells (so-called check-
point inhibitors), such as cytotoxic T lymphocyte-associated pro-
tein 4 (CTLA-4) or programmed cell death 1 (PD-1), have
shown promising results in clinical trials and were approved as
routine therapeutic drugs for deﬁned advanced malignancies.12
The cell surface protein CD47, also known as integrin-associated
protein (IAP), is a member of the immunoglobulin superfamily.
In addition to its function as a receptor for integrins and throm-
bospondin 1 (TSP-1), CD47 plays an important role in various
cellular processes such as immune cell activation, cell migration
and neuronal development.13-17 Recent research activities, how-
ever, were focussed on the role of CD47 in the inhibition of
phagocytosis. CD47 binds to signal regulatory protein a (SIRPa)
expressed on macrophages, resulting in the dephosphorylation of
myosin and inhibition of the phagocytic contractile engulfment
machinery.18 Normal cells present the “don’t eat me” signal
CD47 as a marker of self to macrophages, and loss of CD47
expression in senescent or apoptotic cells results in phagocyto-
sis.19-22 CD47 is highly expressed in multiple human cancer
types, such as acute and chronic myeloid leukaemia, non-Hodg-
kin’s lymphomas and multiple myeloma, leiomyosarcoma, glio-
blastoma and various carcinomas including bladder, ovarian,
hepatocellular, prostate, breast and colon.23-29 Blocking of CD47
on cancer cells results in enhanced macrophage phagocytic activ-
ity and elimination of tumours in various murine models.23,24,26-
29 In the present study, we addressed the question as to whether
CD47 is upregulated in DMM cells as compared to benign
mesothelial cells and might serve as a diagnostic biomarker and
potential therapeutic target for DMM.
Results
The “don’t eat me” signalling molecule CD47 is expressed
in diffuse malignant mesothelioma
CD47 overexpression has been found in multiple malignancies,
such as various carcinomas, glioblastoma and leiomyosar-
coma.23,24 To test if CD47 is expressed in DMM as well, we ana-
lysed a publicly available microarray dataset (GSE2549) that
includes surgical samples of 40 patients suffering from pleural
DMM as well as 5 normal pleura specimens.30 CD47 mRNA
expression was signiﬁcantly higher in DMM as compared to nor-
mal pleura (Fig. 1A). In addition, we observed a trend towards
higher mRNA expression of calreticulin (CALR), the dominant
pro-phagocytic molecule on cancer cells.31 Furthermore, we ana-
lysed the expression of markers commonly used in cytology and
surgical pathology to discriminate DMM from reactive mesothelial
cells.3,5 As expected, DMM showed signiﬁcantly higher mucin 1
(MUC1/EMA) mRNA expression than normal pleura, which is in
line with higher EMA protein expression in DMM.5 In contrast,
no differences were found for desmin (DES), solute carrier family 2
member 1 (SCL2A1/GLUT1) and BAP1mRNAs (Fig. 1A).
FACS analysis of different DMM cell lines showed strong
surface CD47 protein expression in 5/5 cell lines tested, and
calreticulin was detected on the cell surface in 3/5 cell lines
(Fig. 1B-C). In addition, CD47 was detectable by IHC of cell
blocks generated from the different cell lines (Fig. 1D and data
not shown).
These data indicate that DMM cells express the “don’t eat
me” signalling molecule CD47 and the pro-phagocytic mole-
cule calreticulin.
High CD47 expression discriminates DMM from reactive
mesothelial cells in effusion cytology specimens
To investigate whether CD47 can be used as a biomarker for
DMM, we constructed tissue TMAs of cell blocks from pleural
and peritoneal effusions collected from 2010–2014 at the divi-
sion of cytopathology of our institute. CD47 expression levels
by IHC were signiﬁcantly higher in DMM than in benign
mesothelial cells (p < 0.0001, Chi-square test). DMM tumour
cells were CD47 high (2C, 3C) in 24/38 (63%) DMM samples,
whereas reactive mesothelial cells were CD47 low (0, 1C) in all
of the 87 benign samples tested (Fig. 2A-B and Table 1). BAP-1
was deﬁcient in 21/37 (57%) of DMM samples, while 0/103
(0%) of non-neoplastic samples were BAP-1 deﬁcient. Repre-
sentative examples of stainings for EMA, GLUT-1, desmin and
calreticulin are displayed in Fig. 2A-B and data are summarized
in Tables 1 and 2. Importantly, the combination of high CD47
expression and/or BAP-1 deﬁciency was 78% sensitive (28/36
DMM samples) and 100% speciﬁc (0/87 reactive samples). This
two-marker panel was easier to perform and showed greater
sensitivity and speciﬁcity than combination of 4 established
markers BAP-1, EMA, GLUT-1 and desmin (Table 1).
Calreticulin was expressed at signiﬁcantly higher levels in
DMM than in benign mesothelial cells (p < 0.0001, Chi-square
test). In DMM, calreticulin expression was not statistically asso-
ciated with CD47 expression levels (Table 2).
In summary, these data indicate that high CD47 expression
on mesothelial cells can be used as a biomarker for DMM and
that a two-marker combination of CD47 and BAP-1 is a sensi-
tive, speciﬁc and easy to perform assay to discriminate DMM
from reactive mesothelial cells in body cavity effusions.
Targeting CD47 inhibits growth and promotes
phagocytosis of DMM cell lines
In addition to inhibit phagocytosis of tumour cells by binding
to SIRPa on macrophages22,26,27,32, CD47 signalling has also
been shown to stimulate tumour cell proliferation directly by
activating the PI3K/Akt pathway.33 To address whether target-
ing CD47 could represent a therapeutic strategy for DMM, we
cultured DMM cell lines in the presence of IgG isotype control
or blocking anti-CD47 monoclonal antibody (mAb). Numbers
of DMM cells per well were up to two-fold higher in IgG-
treated conditions than in the presence of anti-CD47 mAb after
three days of culture (Fig. 3A), indicating that blocking CD47
directly inhibits DMM cell growth. In addition, to investigate if
blocking CD47 also increases phagocytosis of DMM cells, we
performed a well-established in vitro phagocytosis assay by co-
culturing human macrophages with ﬂuorescently labelled
ACC-MESO-1 cells (Fig. 3B).24,27 Blocking of CD47 resulted in
a two-fold increase in the phagocytosis of ACC-MESO-1 cells
by macrophages compared to control IgG treatment, as ana-
lysed by FACS (Fig. 3C-D).
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These data indicate that blocking CD47 directly inhibits the
growth and increases macrophage-mediated phagocytosis of
DMM tumour cells.
Surgical specimens from patients as well as mouse DMM
tumours express CD47 and are heavily inﬁltrated by
macrophages
To address if CD47 is expressed in DMM tissue sections from
patients and whether this correlates with the expression in cor-
responding cytological effusion cell blocks, we performed IHC
on surgical DMM resection specimens. Fig. 4 shows the com-
parison of the matched cytological effusion specimens and sur-
gical resections for patients 2 (cytology CD47 2C) and 3
(cytology CD47 0), respectively. Interestingly, moderate to high
levels of CD47 were expressed in tissue sections of all patients
analysed, including patients that had low or negative CD47
expression in cytology. In contrast, sarcomatoid tumours
tended to show faint cytoplasmic CD47 staining only (Figure
S1 and data not shown). In addition, we performed stainings
for the macrophage markers CD68 and CD163 that showed
heavy inﬁltration by macrophages in all DMM tumours ana-
lysed (Figs. 4 and S1 and data not shown).
Furthermore, we investigated CD47 expression and tumour
inﬁltration by macrophages in a well-established syngeneic
mouse DMM model.34 Mouse DMM tumours showed high
CD47 expression and were heavily inﬁltrated by macrophages,
as analysed by immunohistochemistry for CD68 and F4/80
(Fig. 5A). In line with this, Cd47, Cd68 and Adgre (F4/80)
mRNA expression was detectable in mouse DMM tumours
(Fig. 5B).
These data indicate that in both humans and mice, CD47 is
expressed in the united cell structures of solid DMM tumours
and that these tumours are heavily inﬁltrated by macrophages.
Figure 1. The “don’t eat me” signal CD47 and the pro-phagocytic molecule calreticulin are expressed in diffuse malignant mesothelioma. (A) Relative expression of CD47,
CALR, MUC1 (EMA), DES, SLC2A1 (GLUT1) and BAP1 mRNA in normal pleura (NP; n D 5) vs. pleural DMM (n D 40) were analysed in a publicly available microarray dataset
(GSE2549) using the Gene Expression Omnibus GEO2R online tool. (B) CD47 and calreticulin expression on mesothelioma cell lines ACC-MESO-1 and H28, respectively, as
analysed by FACS. One representative histogram of 9 (ACC-MESO-1) and 4 (H28) per staining is shown. Red lines, CD47 and calreticulin stainings; blue lines, respective
isotype controls. (C) Mean ﬂuorescence intensities (MFI) of CD47 vs. isotype (left panel) and calreticulin vs. isotype (right panel) in 5 different DMM cell lines. (D) Immuno-
histochemistry for CD47 on FFPE cell blocks from DMM cell lines. Examples of low (1C) and high (3C) CD47 expression are shown. Scale bars, 50mm. Statistics: (A) Mann-
Whitney test; (C) paired t-test. p < 0.05; p < 0.0001
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Discussion
DMM is one of the deadliest cancers and remains a diagnostic
and therapeutic challenge. Based on the historical use of asbes-
tos, the most important cause of DMM, and the decades-long
delay of disease onset, the DMM pandemic is predicted to peak
around 2020 with an estimated 43,000 annual deaths
worldwide.35 Current therapy for DMM is most often an indi-
vidualized multimodality approach that includes, if possible,
surgery with or without intraoperative chemotherapy, radiation
therapy, and systemic chemotherapy.2,36 The role of surgery,
consisting of different more or less radical procedures including
extended pleuropneumonectomy and decortication, remains
controversial. 85–90% of patients are diagnosed in an
advanced, inoperable disease stage, and radical surgical proce-
dures are associated with high postoperative mortality rates up
to 12% and signiﬁcant morbidity.36 Radiation therapy has
traditionally most commonly been used for palliation of symp-
toms in advanced cases as well as an adjuvant therapy in
Table 1. Immunohistochemical ﬁndings in cell block TMAs.
Marker DMM Benign/reactive
CD47-high (2C, 3C) 24/38 (63%) 0/87 (0%)
BAP-1 deﬁcient 21/37 (57%) 0/103 (0%)
CD47-high and/or BAP-1 deﬁcient 28/36 (78%) 0/87 (0%)
Desmin loss 36/36 (100%) 19/65 (29%)
GLUT-1 positive 23/39 (59%) 7/87 (8%)
EMA positive 25/38 (66%) 17/80 (21%)
BAP-1 deﬁcient and/or 1 out of desmin,
GLUT-1, EMA abnormal
34/34 (100%) 28/53 (53%)
BAP-1 deﬁcient and/or 2 out of desmin,
GLUT-1, EMA abnormal
32/34 (94%) 8/53 (15%)
BAP-1 deﬁcient and/or all 3 out of desmin,
GLUT-1, EMA abnormal
26/34 (76%) 2/53 (4%)
Table 2. Calreticulin immunostaining on cell block TMAs.
DMM Benign/reactive
Calreticulin-high 16 70
Calreticulin-low 22 18
DMM, CD47 high (2C, 3C) DMM, CD47 low (0, 1C)
Calreticulin-high 9 7
Calreticulin-low 15 5
Figure 2. CD47 immunohistochemistry discriminates DMM from reactive mesothelial cells in effusion cytology. (A-B) Representative examples of different CD47 immuno-
histochemistry staining intensities in DMM and reactive effusions in TMAs constructed of cell blocks from effusion specimens. Each row represents one patient. The corre-
sponding stainings for calretinin, EMA, BAP-1, desmin, GLUT-1, calreticulin and H&E morphology are shown. Staining intensity for the respective molecules was assessed
in mesothelial cells identiﬁed using calretinin. The interpretation of the result is indicated at the upper right of each spot. (A) Diffuse malignant mesothelioma, CD47 stain-
ing intensity low (0) and high (2C, 3C). (B) Reactive effusion, CD47 staining intensity low (0). Scale bars, 100mm; original magniﬁcation 150x. Staining assessment: CD47
(membranous staining): 0, negative; 1C, incomplete or weak; 2C, complete, moderately strong; 3C, complete, strong. EMA (membranous staining, modiﬁed according
to 5): lo, negative or 1C and <25% positive cells; hi, 2C or 3C or 4C and 25% positive cells. BAP-1 (nuclear staining): L, lost; R, retained. Desmin (cytoplasmic staining):
-, loss in any number of mesothelial cells; C, no loss. GLUT-1 (membranous staining): -, negative; C, positive. Calreticulin (cytoplasmic and membranous staining): lo,
<95% positive cells; hi, 95% positive cells.
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patients undergoing surgery. In the advent of emerging
immune checkpoint inhibitor therapies, however, radiation
therapy may be increasingly used with the intent to induce
immunogenic cell death.2,37 A recent phase 2–3 clinical trial
of anti-CTLA-4 mAb vs. placebo in advanced DMM
(NCT01843374) did not show any beneﬁt of the immune
checkpoint inhibitor as a monotherapy.38 Historically, the only
treatment that has shown signiﬁcant improvements in outcome
is systemic chemotherapy39,40; however, clinical trials with dif-
ferent mAbs targeting the PD-1 pathway are ongoing and
might show promising results in the future, especially if com-
bined with radiotherapy or other targeted therapies.38,41
In the present study, we have identiﬁed the “don’t eat me” sig-
nal CD47 as both a diagnostic marker and a potential therapeutic
target in DMM. Targeting the CD47-SIRPa interaction to
increase the phagocytosis of tumour cells is currently being inves-
tigated in several early-phase clinical trials in haematological
malignancies (NCT02641002, NCT02663518, NCT02678338,
NCT02953509) and solid tumours (NCT02216409, NCT0
2890368, NCT02953782). The expression of CD47 mRNA in
DMMwas ﬁrst identiﬁed in 2005 by Gordon et al. in a large-scale
transcriptional proﬁling study30. In 2010, Melotti et al. reported
the expression of CD47 protein as analysed by FACS of mesothe-
lioma cell lines generated from four primary DMM samples.42
However, a systematic analysis of the role of CD47 in DMM
biology was not performed in these studies. To our knowledge,
we present here the ﬁrst study on the role of CD47 as a potential
diagnostic marker for malignancy in body cavity effusions and as
a promising therapeutic target for DMM.
Using cell blocks from effusion samples, we found that CD47
protein expression was higher in DMM than in reactive mesothe-
lial cells and – with complete membranous staining of at least
intermediate intensity as cut-off – was 100% speciﬁc and 63%
sensitive in discriminating DMM from reactive mesothelial cells.
A two-marker panel of CD47 and BAP-1 outperformed our pre-
vious routine four-marker panel (BAP-1, EMA, GLUT-1 and
desmin)3,5,11 in terms of sensitivity and speciﬁcity. Of note, CD47
immunostaining was found easier to interpret than those for
EMA, GLUT-1 and desmin. Even though calreticulin was
expressed at signiﬁcantly higher levels in DMM than in benign
mesothelial cells, there was major overlap between both groups,
limiting the diagnostic utility of this marker as a surrogate for
malignancy. Given that our analysis focussed on cytological sam-
ples and that malignant cells are usually absent from effusions
associated with sarcomatoid DMM43, our ﬁndings mainly apply
to the epithelioid subtype of DMM. Histological samples of
selected sarcomatoid and biphasic DMMshowed only weak cyto-
plasmic CD47 staining, indicating that CD47 may be less sensi-
tive for a diagnosis of sarcomatoid DMM in histological samples,
like the reported lower sensitivity of BAP-1 in this setting.44
Figure 3. Blocking CD47 inhibits cell growth and promotes phagocytosis of malignant mesothelioma cell lines. (A) DMM cell lines were cultured in duplicates for three
days in the presence of 5mg/ml isotype control (IgG) or anti-CD47 (aCD47) mAb and cell numbers were assessed daily in a Neubauer chamber using trypan blue staining.
The fold increase in cell growth of IgG- vs. aCD47-treated DMM cell lines is shown for each day. Pooled data from 5 independent experiments. (B) Schematic of phagocy-
tosis assay. Differentiated macrophages were serum starved for 2h and then co-cultured with CFSE-labelled ACC-MESO-1 cells for 2h in the presence of 10mg/ml IgG or
aCD47 mAb, followed by FACS analysis. (C) Representative dot plots of CD45CCD14Cmacrophages containing CFSEC ACC-MESO-1 cells. Non-phagocytized CFSEC tumour
cells are gated in the left panels (top left). (D) Normalized fold increase in phagocytosis of aCD47 vs. IgG mAb-treated co-cultures (IgG D 1). Pooled data from two inde-
pendent experiments run in duplicates or triplicates are shown. Results (mean§SEM), experiment 1: IgG, 18.7% § 2.45%; aCD47 34.78% § 4.28%; experiment 2: IgG
0.73% § 0.12%; aCD47 1.15% § 0.08%. f.i., fold increase. Statistics: (A, D) one-sample t-test (hypothetical value D 1). p < 0.05; p < 0.01.
ONCOIMMUNOLOGY e1373235-5
D
ow
nl
oa
de
d 
by
 [U
niv
ers
itä
tsb
ibl
iot
he
k B
ern
] a
t 0
2:3
1 0
4 O
cto
be
r 2
01
7 
Figure 4. Surgical DMM specimens express CD47 and are heavily inﬁltrated by macrophages. Representative examples of CD47 high (Patient 2) and low (Patient 3)
expressing pleural effusions and matched surgical resection specimens are shown. (A) CD47 immunohistochemistry of the effusion cell block (cf. Fig. 2). (B-E) H&E staining
(B) and immunohistochemistry for CD47 (C), CD68 (D) and CD163 (E). Scale bars, 40mm; original magniﬁcation 400x.
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Importantly, we could demonstrate that blocking CD47 in
vitro directly inhibits the growth of DMM cell lines and
increases their phagocytosis by macrophages. The mechanism
by which CD47 interferes with macrophage phagocytosis has
been well described and analysed in numerous studies.18-29 On
the other hand, how CD47 directly affects cell growth is less
well understood. Sick et al. previously reported that CD47 pro-
motes cell proliferation in astrocytoma cells in a PI3K/Akt-
dependent manner.33 TSP-1, which is overexpressed in malig-
nant mesothelioma45, is a well-known ligand for CD4713,15,
and ligation of CD47 by TSP-1 was shown to induce vascular
smooth muscle cell proliferation.46 Although further analysis of
the exact mechanism by which CD47 directly promotes tumour
cell proliferation in our in vitro cultures was out of the scope of
this study, we propose TSP-1 secreted by mesothelioma cells to
be a likely candidate mediating this effect in an autocrine
manner.
In sum, this study identiﬁes the “don’t eat me” signal CD47
as a diagnostic marker and provides a foundation for further
research into its use as a therapeutic target for DMM.
Materials and methods
Tissue microarrays (TMAs)
Archival cell blocks from body cavity effusions submitted for
cytological analysis were retrieved and corresponding slides
were assessed for the presence of mesothelial cells. Cell blocks
were generated by clotting of sediments with plasma and
Figure 5. CD47 is expressed in a murine model of DMM. A) H&E staining and immunohistochemistry for CD47, CD68 and F4/80 in subcutaneously transplanted primary
abdominal murine mesothelioma tumours. One representative example of n D 5 mice is shown. (B) Expression levels of Cd47, Cd68 and Adgre (F4/80) mRNA in murine
tumours from (A). Scale bars, 50mm; original magniﬁcation 400x.
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thrombin, ﬁxation of clots in formalin and standard histologi-
cal processing. Specimens were classiﬁed as DMM or reactive
mesothelial cells based on the original diagnostic interpretation
and clinical follow-up. For a classiﬁcation as DMM, the pres-
ence of atypical mesothelial cells and conﬁrmation by subse-
quent histological examination, by ancillary testing or clinical
correlation was required. Cases were identiﬁed from a period
from 2010 to June 2014. Out of 52 cases meeting the inclusion
criteria, in 7 there was insufﬁcient cell block material for TMA
construction. 45 DMM cases were included in the TMA. For
inclusion into the control (“reactive”) group it was required
that samples had ultimately been judged as benign during rou-
tine diagnostic work-up and that clinical follow-up did not
indicate malignancy. TMAs were created from cell blocks using
an automated tissue microarrayer (TMA Grand Master,
3DHistech) with a punch diameter of 600 mm.47 The study was
approved by the Ethics Committee of the Canton of Bern (KEK
200/14).
Immunohistochemistry (IHC)
IHC stainings of TMAs and selected full slides of cell blocks
and corresponding histological samples were performed on a
Leica BOND RX automated immunostainer using Bond pri-
mary antibody diluent and Bond Polymer Reﬁne DAB Detec-
tion kit according to the manufacturer’s instructions (Leica
Biosystems). Antibodies, clones and manufacturers are listed in
Table S1. Analysis and interpretation of the staining results
were conducted in accordance with the “reporting recommen-
dations for tumour marker prognostic studies” (REMARK)
guidelines.48 CD47 staining was classiﬁed as low (0, absence of
any membranous staining and 1C, weak or incomplete mem-
branous staining) or high (2C, complete membranous staining
of intermediate intensity and 3C, complete membranous stain-
ing of strong intensity) by two board-certiﬁed surgical patholo-
gists (C.M.S and E.H.). BAP-1 was classiﬁed as proﬁcient
(presence of nuclear staining) or deﬁcient (complete lack of
any nuclear staining in the cell population of interest). EMA
immunostaining was regarded positive if 25% of mesothelial
cells were stained, corresponding to a score of 2C according
to Shen et al.5 Loss of desmin staining was deﬁned as presence
of desmin-negative mesothelial cells. GLUT-1 was classiﬁed as
positive when there was any membranous staining of mesothe-
lial cells. While there was widespread calreticulin staining of
mesothelial cells in essentially all samples, we observed two pat-
terns of immunoreactivity: either diffuse staining of nearly all
mesothelial cells (classiﬁed as high, 95%) or presence of a
substantial fraction of negative mesothelial cells (classiﬁed as
low, <95%). Staining results were required to be attributable to
cells morphologically consistent with mesothelial cells. If
attribution of ﬁndings to mesothelial cells was equivocal, we
referred to stainings for calretinin (a marker of mesothelial
differentiation) performed on consecutive slides from each
TMA block.
Gene expression microarray data
Expression data were derived from the Gene Expression Omni-
bus (GEO) public repository for microarray data and are avail-
able under accession number GSE2549.30
Cell lines
DMM cell lines ACC-MESO-149, ACC-MESO-449, NCI-H2850,
ZL5551 and SPC11151 have been described before. Cell line
identity was tested using a commercial cell line authentication
service (Microsynth).
Flow cytometry / ﬂuorescence activated cell sorting (FACS)
DMM cell lines were cultured to 70% conﬂuence, harvested
using non-enzymatic cell dissociation buffer (Sigma) and
stained for CD47, calreticulin and the respective isotype con-
trols (Table S1) in PBS for 30 min at 4C. Samples were
acquired on a BD LSR II ﬂow cytometer (Becton Dickinson)
and were analysed using FlowJo software (TreeStar).
Growth assay
DMM cell lines were plated in duplicates into 24-well tissue
culture plates at a starting concentration of 104 cells per well
and were cultured for three days in the presence of 5 mg/ml
mouse anti-human CD47 (clone B6H12.2, ThermoFisher) or
isotype control (mouse IgG1, ThermoFisher). Cell numbers per
well were determined daily by trypan blue staining and a Neu-
bauer chamber.
In vitro phagocytosis assay
The in vitro phagocytosis assay was performed as described
before24,27, with slight modiﬁcations. Buffy coats and human
serum were obtained from the Swiss Blood Bank (Interregio-
nale Blutspende SRK, Bern, Switzerland). PBMCs were
enriched from buffy coats by density centrifugation using Lym-
pho Spin Medium (pluriSelect). Monocytes were isolated from
PBMCs using the EasySep Human CD14 Positive Selection Kit
II (Stemcell Technologies) according to the manufacturer’s
instructions. 4–5 £ 106 monocytes per well were differentiated
into macrophages for 7 days in 6-well tissue culture plates in
Iscove’s modiﬁed Dulbecco’s medium supplemented with 10%
human serum, L-glutamine and penicillin/streptomycin. ACC-
MESO-1 cells were harvested using non-enzymatic cell dissoci-
ation buffer (Sigma) and labelled with 5(6)-carboxyﬂuorescein
diacetate N-succinimidyl ester (CFSE) in PBS at a ﬁnal concen-
tration of 20 mM. Macrophages were starved in serum-free
medium for 2 h and 1 £ 106 CFSE-labelled ACC-MESO-1 cells
were added. Cell were co-cultured for 2 h in the presence of 10
mg/ml mouse anti-human CD47 (clone B6H12.2, Thermo-
Fisher) or isotype control (mouse IgG1, ThermoFisher), then
harvested, stained for CD45 and CD14 (Table S1) and analysed
by FACS.
Murine DMM model
The murine DMM model was established by s.c. injection of
2 £ 106 RN5 syngeneic mesothelioma cells34 into the dorsal
ﬂank of 6–8 weeks old C57Bl/6J mice. Tumours were measured
with a calliper weekly and mice were euthanized and tumours
harvested when reaching a volume of 0.25 cm3. A part was ﬁxed
in 4% paraformaldehyde before parafﬁn embedding and a part
was processed for RNA extraction as previously described.52
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Murine mRNA analysis
The expression of selected genes was analysed as previously
described and normalized to the housekeeping gene
b-actin.53,54 Primer sequences are listed in Table S2.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5.0
(GraphPad Software). Data are represented as mean § SEM.
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